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Abstract
Despite advances in genomic science stimulating an explosion of literature
around returning health-related findings, the possibility of returning entire
genome sequences to individual research participants has not been widely
considered. Through direct involvement in large-scale translational genomics
studies, we have identified a number of logistical challenges that would need to
be overcome prior to returning individual genome sequence data, including
verifying that the data belong to the requestor and providing appropriate
informatics support. In addition, we identify a number of ethico-legal issues that
require careful consideration, including returning data to family members,
mitigating against unintended consequences, and ensuring appropriate
governance. Finally, recognising that there is an opportunity cost to addressing
these issues, we make some specific pragmatic suggestions for studies that
are considering whether to share individual genomic datasets with individual
study participants. If data are shared, research should be undertaken into the
personal, familial and societal impact of receiving individual genome sequence
data.
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Context
As DNA sequencing becomes cheaper and more widely available, 
the question of what genomic data could or should be returned 
to an individual research participant has become important 
(Figure 1). To date, most discussion in the literature has focused 
on the relative merits of returning specific health-related findings 
that are either pertinent or incidental to the purpose of sequencing1. 
Strong arguments have been made both for and against returning 
actionable findings2–4, and numerous clinical and research labo-
ratories have developed robust systems for identifying, assessing 
and reporting variants that might fall into this category5.
The option of returning individual ‘raw’ genome sequence data 
– BAM or VCF files (see Table 1) – has thus far received less atten-
tion, and until now the best practice has been not to share sequence 
data with individual participants6. Since the vast majority of the 
public (and indeed most researchers) would be unable to meaning-
fully interpret large and complex genomic datasets, the value of 
returning such data is unclear. However, although there is currently 
no legal avenue for participants to request their data7, and no expec-
tation upon researchers to share data if it negatively affects their 
research8, the public are widely supportive of the idea and anecdo-
tal examples exists of such requests being made9. When surveyed, 
most people indicate that they plan to seek out an interpretation of 
their data, while others wish to access their data simply because it 
is ‘theirs’9. Coupled with the potential benefits – supporting auton-
omy, empowerment, health prevention, reciprocity, and improved 
trust between researchers and society10 – this suggests researchers 
and research institutions have an obligation to consider whether, 
how and specifically what individual sequence data could rea-
sonably be returned to study participants. Moreover, as genome 
sequencing becomes more integrated into mainstream healthcare, 
scientists may come under increasing pressure to accede to 
requests to provide individual research participants with their data. 
Anticipating this development, the UK 100,000 Genomes Project 
Protocol (Genomics England, January 2017, Section 9.1.1; https://
www.genomicsengland.co.uk/information-for-gmc-staff/rare- 
disease-documents/) already states that “patients will have the 
right to request that their whole genome sequencing (WGS) data be 
made available to them.”
Given that such requests are likely to increase, here we outline 
the issues that need to be considered when formulating a policy 
on returning genome sequence data to individual study partici-
pants. Specifically, we address two questions: what are the resource 
implications of returning sequence data and, if it were cost- 
neutral (or specifically funded within the research proposal), 
should a mechanism be provided to facilitate individual-level data 
sharing?
As a case study to illuminate the issues, we use the UK Deci-
phering Developmental Disorders (DDD) Study, a translational 
research project involving whole exome sequencing of nearly 
14,000 clinically-ascertained families (>32,000 exome sequences) 
to find the genetic causes of severe developmental disorders11. 
The DDD study has pioneered a proportionate data sharing 
policy12, which returns likely diagnostic variants to families via  
DECIPHER13 and their local clinical teams, and enables bona fide 
researchers to access anonymised whole exome sequence data from 
the European Genome-phenome Archive under a managed access 
model14. However, the DDD study does not currently return whole 
exome sequence data to individual participants, a decision that was 
reached after careful consideration of the issues outlined below and 
how best to deploy the study’s finite resources.
Figure 1. Options for returning genome sequence data to participants. DDD, Deciphering Developmental Disorders study; ACMG, 
American College of Medical Genetics and Genomics; DTC, direct-to-customer.
Table 1. Genomic sequence data file types and sizes. *GB, gigabytes; WES, whole exome sequencing (i.e. all the protein coding 
regions of the genome, ~50–60 million bases); WGS, whole genome sequencing (~3 billion bases, assumes 30X coverage).
Name Description WES file 
size (GB)
WGS files 
size (GB)
BAM Binary Alignment/Map format: nucleotide sequence with corresponding quality scores 
mapped to the reference genome, derived from raw data files using an alignment algorithm
~5–15 ~150–250
VCF Variant Call Format: files for storing variant bases relative to the reference genome, which 
are derived from sequence files using a variant calling algorithm; usually annotated with 
allele frequency and predicted consequence
~0.02 ~0.2
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Logistical challenges
Even in cases such as the DDD study, where exome sequencing 
data have been generated and there is a direct link (via a clinician) 
to each individual participant, there are still substantial resources 
required to ensure that whole exome data could be safely returned 
to individuals7.
Confirming the data belong to the requestor: the laboratory and 
data management systems utilised by researchers are not gener-
ally required to meet the rigorous quality standards of accredited 
diagnostic laboratories. Therefore, it is imperative to confirm that 
any data generated through a research pipeline actually belongs 
to the individual requesting the data. Sharing person A’s unique 
genomic data with person B, without their knowledge or consent, 
would be a negligent and egregious abuse of trust and, depending 
on the use to which the data were put, could constitute a major 
clinical risk. To solve this problem, a second DNA sample could be 
compared to the dataset using a DNA fingerprint. Resources would 
be needed to support secondary sampling, alongside processes to 
manage sample logistics, DNA extraction, genotyping and data 
analysis.
Providing bespoke informatics support: although some research 
participants may have some degree of personal bioinformatics 
expertise, who may request their data for a variety of reasons, pro-
viding the data in an accessible format would likely require some 
informatics support. Research datasets are frequently generated 
and annotated using experimental bioinformatics pipelines that 
are constantly evolving, and annotations can change substantially 
over time. Additionally, care must be taken to remove annotations 
common in such files that might reveal sensitive information about 
other members of the cohort. It would therefore be necessary to 
develop a specific bioinformatics pipeline to clean any research 
datasets prior to release to participants. Data return options vary 
from a simple encrypted hard drive to a user-friendly secure 
data access portal, which would require substantial resources 
to set-up and manage, but would offer greater equity of access. 
Either option would require some technical management to 
ensure that the correct data are uploaded and accessed by the cor-
rect individual.
Ethico-legal considerations
In addition to the resource-dependent issues identified above, there 
are a number of other issues that need to be considered in studies 
involving patient populations, such as families in the DDD study.
Returning data to family members: since the majority of genetic 
variants are shared between close biological relatives, any returned 
data may have implications for other (un-sequenced) members of 
the family15. Although a single participant may have a right to their 
own genome data, regardless of whether it is “shared” with family 
members, the familial implications should be made clear, and in 
cases where an entire family’s data are requested, consent should 
be sought from all individuals or proxies upon whom data are 
being requested. In addition, paediatric studies, such as DDD, must 
address the thorny issue of returning a child’s genome sequence to 
their parents16, where it is complex to determine who has rights of 
control and to what extent as the child approaches and passes the 
age of majority. There are already well rehearsed arguments that 
attempt to balance an individual’s right to privacy with the desire 
to protect their relatives from harm15, but this issue is even more 
complex within the context of a long-term research study, during 
which time – unbeknownst to the researchers – an individual may 
gain (or lose) the capacity to make a decision about their own data. 
Researchers should be aware of the legal status of the data within 
their jurisdiction, particularly in relation to individuals who lack 
capacity to give consent.
Mitigating against unintended consequences: much of the previ-
ous literature discussing return of individual results from genome 
sequencing studies has focused on the utility of the data and its 
limitations17–19. Our empirical data on attitudes towards the return 
of genome sequence data has shown that while research partici-
pants say they would like access to their ‘raw data’, many have 
unrealistic expectations of what they can do with it, e.g. 43% 
(n=1844) said they would take their raw DNA data to their General 
Practitioner9. Although numerous genome interpretation services 
exist, unlike returning specific health-related findings where the 
onus lies with the research team to develop robust processes for 
identifying and verifying relevant variants, researchers could not be 
held responsible for any participant-initiated or third party analy-
ses of their data. Nonetheless, there are legitimate concerns about 
the moral and legal responsibilities of researchers and research 
institutes for any harm that might befall participants or members 
of their family as a result of data return. There are no regulated 
standards for genomic analysis and very limited consensus between 
existing interpretation services for personal whole genome data20. 
There could also be a substantial impact on clinical services, due 
to interpretation requests and follow-on work, creating a signifi-
cant and potentially unmanageable healthcare demand. Data that 
are analysed in a clinical context could potentially result in litiga-
tion for negligence due to a different interpretation of results, an 
incorrect diagnosis, or even a ‘missed’ life-saving diagnosis. To 
mitigate against these risks, the procedure for data generation 
and processing should follow best practice (to the extent that it is 
defined) and be clearly documented, along with known limitations 
as part of the terms and conditions of receiving data. Researchers 
must be clear that they are not providing a clinical service, but 
participants should be signposted to appropriate sources of 
further information to help them decide what to do next. Within 
the wider ecosystem, development of quality-assured (e.g. “kite-
marked”) websites are needed, which both clinical geneticists 
and genomic scientists should agree are useful for the public.
Ensuring appropriate governance: careful consideration and 
oversight of the issues outlined above is essential for any study 
wishing to return genomic sequence data to individual partici-
pants. There needs to be a formal and transparent process in place 
for making decisions, which involves a number of stakeholders 
involved both in making the initial decision to disclose data and 
in maintaining on-going oversight and ensuring good data govern-
ance. This might include the principal investigators, clinical and 
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research study sponsor(s), professional bodies (including legal 
and ethics representation) and patient representatives.
Conclusions
In the context of the open data movement and the rapid growth of 
genome sequencing, it is likely that researchers will increasingly 
face requests from study participants to access their own data, for 
various reasons. Research studies could potentially face reputa-
tional risk, loss of trust or litigation either from withholding data 
without good reason, or from inappropriate or reckless data return. 
Researchers have a duty to society and their funders to make the 
best use of finite resources, and must balance their moral respon-
sibilities to individual participants with broader responsibilities to 
the whole cohort and the creation of generalizable knowledge (note, 
these duties are often different to the duties of clinicians). Moreo-
ver, erroneous diagnoses arising from over-interpretation of the data 
and poor implementation of genomics could result in real harm to 
patients, particularly in translational studies involving vulnerable 
clinical groups. There is a pressing need for a rigorous public health 
evaluation of the significance of identifying actionable variants in 
asymptomatic individuals with no family history. 
We conclude that unless the return of genomic sequence data to 
individual participants is specifically and appropriately resourced, 
potentially by research funders themselves, to do so could do more 
harm than good. How can we reconcile this with mounting ethical 
arguments in favour of data sharing, and strong empirical support 
for receiving individual genome sequence data? Where resources 
are available to support robust sample and data management21, 
as well as good data governance, returning individual genome 
sequence data to research participants is logistically achievable and 
may also be morally desirable. For studies considering whether to 
share individual genomic datasets with individual study partici-
pants, we make the following pragmatic suggestions: 
(1)   A second sample should be obtained from all requestors to 
verify the provenance of the data;
(2)   Informatics support should be provided to generate 
appropriately processed datasets and enable individuals to 
access their data;
(3)   Research budgets should explicitly include funding to 
support return of individual-level data;
(4)   The research team should document their protocols, proc-
esses and data limitations, and signpost participants to 
quality sources of information;
(5)   Appropriate governance structures should be put in place to 
ensure data access requests are handled correctly, including 
signed consent forms from all requestors;
(6)   Research should be undertaken into the personal, familial 
and societal impact of receiving individual genome 
sequence data.
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